Author:
Mian Paola,Meussen Elvera,Piersma Djura,Lankheet Nienke A. G.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology (medical),Pharmacology,Oncology
Reference7 articles.
1. MEK and RAF inhibitors for BRAF-mutated cancers.;Belden;Expert Rev Mol Med,2012
2. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.;Rose;Drugs Today (Barc),2019
3. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.;Dummer;Lancet Oncol,2018
4. Efficacy, safety, and tolerability of approved combination BRAF and MEK inhibitor regimens for BRAF-mutant melanoma.;Hamid;Cancers,2019
5. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.;Gogas;Eur J Cancer,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Encorafenib overdose;Reactions Weekly;2021-03